[Blood coagulation inhibitors and thrombosis].
Pathological inhibitors of the coagulation which are recognized by characteristic laboratory findings may cause an increased inclination to haemorrhage, may be clinically mute or also may effect an increased inclination to thrombosis (lupus inhibitors). It is reported on patients with rare coagulation inhibitors, a pathologic antithrombin with normal reptilase time and an antithromboplastin with protracted effect, in which thromboses appeared. The occurrence of thromboses in these patients up to now does not allow the assumption of an effect of these inhibitor substances furthering thrombosis, but only the statement that despite coagulation-analytically recognizable inhibition effects the development of a thrombosis is not prevented. A prophylactic factor substitution in operative interventions is not indicated.
Lutze
G
G
Institut für Klinische Chemie und Laboratoriumsdiagnostik, Medizinischen Akademie Magdeburg.
Franke
D
D
Presser
H J
HJ
Grüngreiff
K
K
D000328:Adult; D000991:Antithrombins / Q000378:metabolism*; D005260:Female; D006474:Hemorrhagic Disorders / Q000097:blood; D006801:Humans; D008297:Male; D013918:Thrombin Time; D013924:Thrombophlebitis / Q000097:blood; D013925:Thromboplastin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000097:blood*
D000991:Antithrombins; D013925:Thromboplastin
Gerinnungsinhibitoren und Thrombose.